In this single-centre registry, we evaluated the clinical outcomes of 151 consecutive patients with NSTE-ACS and ULMCD who underwent percutaneous coronary intervention with drug-eluting stents from 2005 to 2009.
Overall in-hospital major adverse cardiac event (MACE) rate was 5.3 % , mortality rate was 0.7 % . At 30 months ¡À 15 months, 30 patients (19.9 % ) experienced MACE. The 4-year cumulative survival rate of no MACE was 73.2 % and cumulative survival rate was 90.6 % . Left ventricular ejection fraction (hazard ratio [HR] 0.947; 95 % confidence interval [CI], 0.898-0.998; P = 0.043) and SYNTAX [SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery] score ?33 (HR 1.28; 95 % CI, 1.025-1.433; P = 0.029) were associated with MACE, while only left ventricular ejection fraction (HR 0.82; 95 % CI, 0.69-0.973; P = 0.023) was associated with mortality.
Our study demonstrates the feasibility of percutaneous coronary intervention with drug-eluting stents in patients with NSTE-ACS and ULMCD. The early and long-term outcomes were acceptable. Left ventricular ejection fraction and SYNTAX score ?33 predict MACE and only left ventricular ejection fraction predicts mortality.